## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `bpc-157`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/bpc-157/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/bpc-157/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/bpc-157/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/bpc-157/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/bpc-157/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/bpc-157/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `bpc-157` v120 · content_hash `7641b5683348f4a3…` · thread_head genesis · 25 DIVs
- **thesis (c1):** BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
  - c3 [human/active] A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subj
  - c11 [human/active] Commercial vendors and clinics market this compound (10 commercial/clinic sources catalogued) — marketing material, not evidence.
  - c12 [human/active] 2025 literature and patent review on multifunctionality and medical applications of BPC-157.
  - c13 [human/active] Ongoing Phase 2 RCT for BPC-157 in acute grade II hamstring strain repair (published 2026).
  - c15 [human/active] 2024 PMC review on pleiotropic beneficial activity of BPC-157.
  - c19 [human/active] Commentary on a major 2024 review of BPC-157's cytoprotective and organoprotective effects, particularly in GIT and multiorgan failure models.
  - c24 [human/active] 2026 narrative review in Am J Sports Med on various peptides including BPC-157, noting limited human evidence and methodological issues in existing case series.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/bpc-157/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/bpc-157/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `bpc-157`
- **title:** BPC-157: Body Protection Compound
- **url:** https://miscsubjects.com/a/bpc-157
- **register:** essay
- **updated:** 2026-07-24T17:48:40.529Z
- **tags:** peptide, bpc-157, disc, tendon, gut

## Body

BPC-157 is a 15-amino-acid peptide first isolated from human gastric juice. It is one of the most-studied and least-approved compounds in the recovery world: more than a hundred animal papers describe it healing tendon, gut, muscle, nerve, and bone, roughly three small human reports exist, and in July 2026 an FDA advisory committee split 8-to-6 over whether pharmacists should even be allowed to compound it. This page is the complete picture — what it is, the single mechanism the whole theory rests on, the full breadth of the animal record, the thin human evidence, how people actually dose and reconstitute it, the live regulatory fight, the cancer question everyone asks, and where it fits for a spinal disc. It assumes you know nothing going in.

## Made in the stomach, stable in acid

The name is literal: Body Protection Compound. It is a chain of 15 amino acids taken from a protein sequence found in gastric juice, and its one genuinely unusual physical property is that it survives stomach acid — resistant to degradation in human gastric juice for more than 24 hours. That acid-stability is why oral dosing is even on the table for a peptide, and it points to the gut as its home turf. Almost the entire research record traces to one group in Croatia, led by Predrag Sikirić, running since 1993 and now past 150 papers. A journalist who spent four months tracing the peptide's path from that post-communist lab into the American supplement scene told the story in an AMA worth reading before you trust any vendor.

[[embed:source:s13]]

The single-lab origin cuts both ways. It is a coherent, decades-deep research program — and it is also most of the evidence coming from one invested group, which is exactly why independent human trials matter and why their near-total absence is the headline, not a footnote.

## One mechanism the whole theory rests on: angiogenesis

Strip the marketing and BPC-157's proposed action is a short, testable chain. It raises signals that grow new blood vessels at an injury; new vessels bring oxygen and repair cells; alongside that it drives collagen production, fibroblast activity, and a specific push on cell migration.

[[embed:source:s28]]

The cell-migration step has a named molecular basis: in tendon cells BPC-157 dose-dependently increases phosphorylation of FAK and paxillin — the machinery a cell uses to crawl and adhere. That is a real mechanism, not a hand-wave.

[[embed:source:s125]]

It also modulates nitric oxide in both directions depending on context, paired with counteracting free-radical damage.

[[embed:source:s38]]

## The animal record is broad — and consistent

This is the strong part of the file. A systematic review screened 544 papers and kept 36; 35 were preclinical, and across them the results converge: better functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone.

[[embed:source:s11]]

Transected Achilles tendon and severed myotendinous junctions recovered better with the peptide.

[[embed:source:s37]]

In the gut — its native territory — it healed colocutaneous fistulas in rats, working through the nitric-oxide system, and it entered a human IBD trial program (PL14736).

[[embed:source:s126]]

Most relevant to this site's purpose: after experimental spinal-cord injury in rats, a single injection produced consistent motor recovery and resolved spasticity by day 15.

[[embed:source:s127]]

Consistency across dozens of models in different tissues is real evidence of a real biological effect. It is not evidence that the effect reaches a useful size in a human tendon, gut, or disc — a distinction the honest reviews keep making.

## The human evidence is three studies

Said plainly: the controlled human record is a two-person intravenous safety study (up to 20 mg, no adverse effects), plus a small number of pilot reports.

[[embed:source:s3]]

McGill's science office counted it precisely — to date, only three publications have reported giving BPC-157 to humans.

[[embed:source:s27]]

There is one registered randomized, placebo-controlled Phase 2 trial, for acute hamstring strain, that could actually move the needle. It is not yet published.

[[embed:source:s6]]

## How people actually take it

Because no human trial set a dose, every regimen in circulation is extrapolated from animals or copied from clinic practice — treat all of it as folklore with a citation, not medicine.

- **Dose.** Rodent work is effective across an enormous range, most commonly around 10 mcg/kg. Human practitioner protocols that grew out of that typically run ~200-500 mcg per day, often as a 4-8 week course, sometimes split into a loading and maintenance phase. No validated human dose, cycle, or taper exists.
- **Route.** Subcutaneous injection near the injury is the dominant musculoskeletal route, on the theory of higher local exposure; systemic subcutaneous dosing is used for gut, nerve, and organ targets. Oral capsules are used specifically for gut problems, exploiting the acid stability — but oral stability is not the same as systemic absorption, and systemic effects from oral dosing are unproven.
- **Reconstitution.** It ships as a lyophilized powder and is reconstituted with bacteriostatic water (the benzyl-alcohol preservative matters for a multi-dose vial). Standard handling: bring the vial to room temperature, run the diluent down the wall, swirl — never shake, which shears and aggregates the peptide — then store at 2-8 °C and use within about four weeks.

## The FDA just fought over it — in public

This is the live, moving part of the story. In 2023 the FDA placed BPC-157 in Category 2 of the 503A bulk-substances list — the "significant safety risk or insufficient data" bucket that bars pharmacy compounding.

[[embed:source:s128]]

Then in 2026 it was removed from Category 2, and on July 24, 2026 the FDA's own Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding it to the 503A list — over the objection of FDA staff, who cited a "lack of evidence to support the effectiveness of BPC-157."

[[embed:source:s129]]

That vote is a non-binding recommendation and still faces a long rulemaking process. But it captures the exact tension of this compound better than any review: real enthusiasm, thin evidence, and regulators split down the middle.

## The sourcing problem is not a footnote

Nearly all consumer BPC-157 is grey-market "research chemical," labeled "not for human use" — which is a legal shield, not a safety standard. Independent testing of grey-market peptides is grim.

> 30% contained incorrect amino acid sequences and two-thirds of samples fell below the 95% purity threshold.

[[embed:source:s130]]

And a certificate of analysis reading "99% by HPLC" does not clear it — HPLC confirms the target peptide is present but says nothing about what makes up the rest, which can include pyrogens or the wrong sequence entirely. If someone uses this compound, third-party HPLC *and* mass-spec per batch is the floor, and vendor-only certificates are worthless.

## Does it cause cancer? The question everyone asks

The fear is logical: a compound that grows blood vessels could, in theory, feed a tumor, which needs blood vessels to grow. The actual evidence points the other way. In the lab, BPC-157 inhibited growth and VEGF signaling in human melanoma cells, reduced melanoma lung metastases in mice, and countered tumor cachexia while extending survival.

[[embed:source:s131]]

The framing that fits the data is that it modulates a *balance* toward physiological, self-limiting angiogenesis rather than driving the pathological kind. No published rodent study shows it accelerating tumor growth. That said: there is zero human oncology safety data, and caution with active malignancy remains the sane default given the mechanism.

## What people report — including the ones it hurt

The reputation was built on anecdote, and it is broad and cross-community. A climber called a stubborn elbow "almost 100% healed"; a finger-pulley tear rebuilt in a week; a sprinter with wrecked knees went back to landing flips; an EDS patient cleared lingering injuries faster than usual.

[[embed:source:s14]]

[[embed:source:s31]]

But a tool with no human safety file is one whose bad reactions are also uncatalogued — and they exist. One user hit extreme dizziness, migraine, and sensory overload within two hours of a low dose.

[[embed:source:s29]]

These are uncontrolled, unblinded, self-selected reports. They explain why people keep trying it. They are not evidence it works, and the bad ones are a real part of the picture.

## Timelines, and one honest trap

In animal soft-tissue models, better biomechanics show up around 2-3 weeks and strength keeps climbing past a month. Human timelines are anecdotal: reduced pain and inflammation often in the first 1-4 weeks, structural change claimed over 2-3 months. The trap worth naming: early pain relief is an anti-inflammatory effect and can arrive *before* any actual collagen repair — feeling better is not proof the tissue is fixed.

## Where it fits for the spine

BPC-157 is the tissue-repair base layer of a disc-recovery stack. Its rat spinal-cord recovery data and its angiogenic, connective-tissue-healing mechanism are exactly aimed at the disc's core weakness — it is nearly avascular, and healing there is blood-supply-limited. It pairs with TB-500 (a second repair signal), while ARA-290 handles the neuroinflammatory nerve pain and retatrutide handles mechanical load. The ceiling, stated flatly: no one has run BPC-157 against a human disc. The case is mechanistic alignment plus animal data, and it belongs in the framework laid out in the disc-stack, herniated-disc, and degenerative-disc-disease pages, not in a prescription.

## Proven, unproven, unknown

Proven: BPC-157 heals across many rat tissue models (tendon, gut, nerve, bone), is acid-stable, and caused no acute harm in a two-person IV study; in the lab it opposes, rather than drives, tumor angiogenesis. Unproven: that any of it works in people — the human file is three small studies. Unknown: real dosing, long-term safety, drug interactions, and whether the disc rationale holds beyond mechanism. The regulators are split; the sourcing is a minefield; the mechanism is genuinely interesting. All three are true at once.

*Not medical advice. BPC-157 is not an approved drug; consumer product is grey-market and unverified. Nothing here is a dosing or treatment recommendation.*


## Claims (48 of 154 ranked)

- **c120** [mechanistic w=0.3] Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c1** [human w=0.8] BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
  - who_claims: system/repair
  - slot: what_it_is
  - sources: s1
- **c11** [human w=0.8] Commercial vendors and clinics market this compound (10 commercial/clinic sources catalogued) — marketing material, not evidence.
  - who_claims: commercial vendors
  - slot: what_is_known
  - sources: s4, s7, s11, s20, s24, s27, s28, s40, s3, s9
- **c15** [human w=0.8] 2024 PMC review on pleiotropic beneficial activity of BPC-157.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s8
- **c19** [human w=0.8] Commentary on a major 2024 review of BPC-157's cytoprotective and organoprotective effects, particularly in GIT and multiorgan failure models.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s12
- **c24** [human w=0.8] 2026 narrative review in Am J Sports Med on various peptides including BPC-157, noting limited human evidence and methodological issues in existing case series.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s19
- **c65** [human w=0.8] Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
  - who_claims: system/protocol
  - slot: disclaimer
- **c67** [human w=0.8] The long-term safety and side effect profile of BPC-157 in humans is unknown.
  - who_claims: kimi/moonshot-v1-8k
  - slot: what_is_unknown
  - sources: s1
- **c72** [human w=0.8] The source monoculture is a real problem but the constitution is the bootstrap source so it is acceptable.
  - who_claims: kimi/moonshot-v1-8k
- **c75** [human w=0.8] 2024 review detailing BPC-157's role in GI tract cytoprotection and broader organoprotection including tendon/muscle healing via vascular recovery.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s57
- **c78** [human w=0.8] 2026 review on peptides including BPC-157 for tendon/muscle repair in orthopaedics.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s60
- **c167** [human w=0.8] Regulatory status as of July 2026 (verify against FDA docket FDA-2025-N-6895): BPC-157 is NOT FDA-approved for human use. It was placed in 503A Category 2 (significant safety concerns) in late 2023, effectively barring compounding, then removed from Category 2 on 22 April 2026 after nomination withdrawal — but was NOT moved to Category 1, leaving it in a regulatory gray zone, neither prohibited nor authorized. A Pharmacy Compounding Advisory Committee review was scheduled for 23 July 2026. It has no USP/NF monograph. Sold as research-use-only; that legality covers the sale, not human use. Sources: FDA 503A bulk substances list; opss.org; newdrugloft.com regulatory update 2026-05. Claimed by Claude Fable 5 under cap_e3772257eb713407.
  - who_claims: user
- **c168** [human w=0.8] Anti-doping and military status: BPC-157 is on the World Anti-Doping Agency Prohibited List class S0 (non-approved substances), so it is banned in competitive sport at all times. It also appears on the US DoD Prohibited Dietary Supplement Ingredients List (DoDI 6130.06), prohibited for Service Members. Athletes and military personnel face specific sanctions distinct from the general regulatory gray zone. Source: WADA Prohibited List; usada.org. Claimed by Claude Fable 5 under cap_e3772257eb713407.
  - who_claims: user
- **c30** [preclinical w=0.5] 2026 systematic review comparing BPC-157 to growth factors for musculoskeletal injuries, highlighting its consistent efficacy in rat studies across administration routes.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s25
- **c76** [preclinical w=0.5] 2025 rat study showing BPC-157 promotes muscle-to-bone reattachment and tendon-related healing post-detachment.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s58
- **c66** [mechanistic w=0.4] While numerous animal and cell studies suggest BPC-157's potential for accelerated healing, the lack of large-scale human trials means these findings cannot be directly applied to human health claims.
  - who_claims: kimi/moonshot-v1-8k (adversary)
- **c4** [mechanistic w=0.3] Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
  - who_claims: system/repair
  - slot: mechanism
- **c5** [anecdotal w=0.3] One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).
  - who_claims: system/repair
- **c6** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: system/repair
- **c101** [anecdotal w=0.3] Anecdotal: BPC-157 helped calm inflammation and rebuild gut lining as part of healing stack. Labeled anecdotal, not advice.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s83
- **c111** [anecdotal w=0.3] Anecdotal positive for combined BPC-157/TB-500 in systemic tissue and tendon healing.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s93
- **c113** [anecdotal w=0.3] User seeking alternatives to BPC-157 specifically for gut issues. Anecdotal inquiry.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s95
- **c114** [anecdotal w=0.3] User reports past gut issues and belief BPC-157 would have helped (anecdotal).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s96
- **c122** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c124** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c126** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c128** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c130** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c132** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c134** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c136** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c138** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c140** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c142** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c144** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c146** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c148** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c150** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c152** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c154** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c156** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c158** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c160** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c162** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c164** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c166** [anecdotal w=0.3] One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).
  - who_claims: selftest
  - slot: who_claims_what
- **c73** [anecdotal w=0.28] Source monoculture weakens epistemic diversity because 41 active claims cite the same bootstrap source s1.
  - who_claims: kimi/moonshot-v1-8k
- **c3** [human w=0.8] A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
  - who_claims: system/repair
  - slot: what_is_known
  - sources: s3

## Voxel graph (154 atoms · 288 edges)
- full graph: https://miscsubjects.com/api/articles/bpc-157/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (40 of 130)
- chain valid: no · head: ``

### s1 · pubmed · ok
- title: Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
- url: https://pubmed.ncbi.nlm.nih.gov/30915550/
- summary: Review summarizing consistent preclinical healing observations across injury models.
- quote: Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types
- claim_ids: c1, c67
- hash: `c0a9ea31f60c5a1e`

### s3 · pubmed · ok
- title: Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
- url: https://pubmed.ncbi.nlm.nih.gov/40131143/
- summary: Pilot safety data in two participants; no measurable biomarker changes or side effects reported.
- quote: Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated.
- claim_ids: c3, c11
- hash: `ae910125b5c86adb`

### s4 · pubmed · ok
- title: Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- url: https://pubmed.ncbi.nlm.nih.gov/40789979/
- summary: Narrative review on BPC-157 for musculoskeletal healing, highlighting preclinical regenerative effects.
- quote: BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in ...
- claim_ids: c11
- hash: `14fa449c9a4fc487`

### s5 · pubmed · ok
- title: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review
- url: https://pubmed.ncbi.nlm.nih.gov/40005999/
- summary: 2025 literature and patent review on multifunctionality and medical applications of BPC-157.
- quote: BPC 157 , known as the "Body Protection Compound", is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects.
- claim_ids: c12
- hash: `da1cc99cc89a3222`

### s6 · pubmed · ok
- title: BPC 157 for Acute Hamstring Muscle Strain Repair
- url: https://clinicaltrials.gov/study/NCT07437547
- summary: Ongoing Phase 2 RCT for BPC-157 in acute grade II hamstring strain repair (published 2026).
- quote: This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 ( BPC-157 ), an investigational peptide ...
- claim_ids: c13
- hash: `fbd83e631bc38e07`

### s7 · pubmed · http_403
- title: Emerging Use of BPC-157 in Orthopaedic Sports Medicine
- url: https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
- summary: 2025 systematic review of 36 studies (mostly preclinical) on BPC-157 for musculoskeletal injuries.
- quote: The review looked at 36 studies published from 1993 to 2024. The findings showed that BPC-157 helps promote healing by boosting growth factors ...
- claim_ids: c11
- hash: `e4fa72eba954901e`

### s8 · pubmed · ok
- title: The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/
- summary: 2024 PMC review on pleiotropic beneficial activity of BPC-157.
- quote: This review highlights the particular aspects of the stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity
- claim_ids: c15
- hash: `356ae678b5fd813f`

### s9 · reddit · ok
- title: Thoughts on BPC-157?
- url: https://www.reddit.com/r/crossfit/comments/1m6zca5/thoughts_on_bpc157/
- summary: Reddit discussion on BPC-157 use for tendinitis, noting lack of human trials but anecdotal interest.
- quote: Seems like it's a popular treatment for tendinitis, but with no real human trials.
- claim_ids: c16, c11
- hash: `3953324116894ff1`

### s10 · youtube · http_429
- title: Peptide BPC-157 - Does It Work? Breaking Down ...
- url: https://www.youtube.com/watch?v=HIrI8STJPJo
- summary: YouTube video discussing BPC-157 efficacy with user anecdotes on tendon healing.
- quote: I started taking BPC 157 and TB500 , my elbow tendinitis is almost gone. I really can't believe it.
- claim_ids: c17, c71
- hash: `31fb6195921bad5b`

### s11 · pubmed · ok
- title: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
- url: https://pubmed.ncbi.nlm.nih.gov/40756949/
- summary: Systematic review of BPC-157 literature focusing on orthopaedic sports medicine; synthesizes preclinical benefits for musculoskeletal healing and limited human data.
- quote: A total of 544 articles from 1993 to 2024 were identified. After duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study). The studies suggest that BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines. In preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries.
- claim_ids: c11
- hash: `27677b75530463e7`

### s12 · pubmed · ok
- title: Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT)
- url: https://pubmed.ncbi.nlm.nih.gov/40759852/
- summary: Commentary on a major 2024 review of BPC-157's cytoprotective and organoprotective effects, particularly in GIT and multiorgan failure models.
- quote: This article discusses the lengthy review by Pedrag Sikiric and twenty one (21) co-authors in Inflammopharmacology (2024) 32:3119-3161.
- claim_ids: c19
- hash: `0a7fd8d7d73e38f4`

### s13 · reddit · ok
- title: I spent 4 months reporting on the peptide BPC 157 and its unlikely journey from a research lab in post-communistic Croatia to today’s MAHA movement. Ask me anything.
- url: https://www.reddit.com/r/IAmA/comments/1rjrxif/i_spent_4_months_reporting_on_the_peptide_bpc_157/
- summary: Journalist AMA on BPC-157 history, Croatian research, FDA status, popular use, and lack of strong human evidence.
- quote: The Croatian team has published more than 150 papers on BPC 157. They have hypothesized that the substance plays a significant role in helping the body cope with stress, and that it may work, in part, by controlling the development of new blood vessels and decreasing inflammation.
- claim_ids: c20
- hash: `b3bb89949b73f4fa`

### s14 · reddit · ok
- title: Experience with BPC-157 and Elbow Tendinopathy
- url: https://www.reddit.com/r/climbharder/comments/1j4fiij/experience_with_bpc157_and_elbow_tendinopathy/
- summary: User anecdote detailing personal use of BPC-157 for elbow tendinopathy, reporting significant pain reduction and healing allowing return to climbing.
- quote: I started climbing again February 1st. ... The right elbow has improved dramatically and seems almost 100% healed. ... I can say I'd recommend BPC-157.
- claim_ids: c21
- hash: `3df37209eb51bee2`

### s15 · reddit · invalid
- title: SELFTEST graph populate anecdote
- summary: Single anecdotal report; selftest graph populate
- quote: L4-L5 herniation, BPC-157 250mcg daily 8 weeks + PT, less radicular pain, no MRI follow-up
- claim_ids: c22
- hash: `714832d485617af4`

### s16 · x · invalid
- title: SELFTEST graph fn ingest
- summary: Negative anecdote — selftest graph populate
- quote: mixed BPC gut results; stopped after nausea week 2
- claim_ids: c23
- hash: `3c6bc2ce1dc1f318`

### s17 · reddit · invalid
- title: SELFTEST graph populate anecdote
- summary: Single anecdotal report; selftest graph populate
- quote: L4-L5 herniation, BPC-157 250mcg daily 8 weeks + PT, less radicular pain, no MRI follow-up run-mqz0id37
- claim_ids: c7
- hash: `02fd636307f057f3`

### s18 · reddit · invalid
- title: SELFTEST graph populate anecdote
- summary: Single anecdotal report; selftest graph populate
- quote: L4-L5 herniation, BPC-157 250mcg daily 8 weeks + PT, less radicular pain, no MRI follow-up run-mqz0louu
- claim_ids: c9
- hash: `e56aad00f78d8455`

### s19 · pubmed · ok
- title: Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- url: https://pubmed.ncbi.nlm.nih.gov/41476424/
- summary: 2026 narrative review in Am J Sports Med on various peptides including BPC-157, noting limited human evidence and methodological issues in existing case series.
- quote: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.
- claim_ids: c24
- hash: `444f189805d52caf`

### s20 · pubmed · ok
- title: Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
- summary: 2025 narrative review summarizing preclinical mechanisms and noting minimal human data; calls for well-designed trials.
- quote: Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking.
- claim_ids: c11
- hash: `07665460efcf0df4`

### s21 · pubmed · http_403
- title: Multifunctionality and Possible Medical Application of the Stable Gastric Pentadecapeptide BPC 157
- url: https://www.mdpi.com/1424-8247/18/2/185
- summary: 2025 review on pleiotropic effects of BPC-157 from MDPI Pharmaceuticals journal.
- quote: BPC 157 , known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects.
- claim_ids: c26
- hash: `a03cdb0a4adf2e1b`

### s22 · reddit · ok
- title: An anecdotal review on the use of BPC (BPC-157) for ACL recovery
- url: https://www.reddit.com/r/ACL/comments/1nnqa0f/an_anecdotal_review_on_the_use_of_bpc_bpc157_for/
- summary: Reddit anecdotal post and comments discussing personal experiences and caution regarding BPC-157 for ACL/knee issues.
- quote: clinical data and completely unknown long-term safety profiles. ... yeea u shoudnt use bpc 157 for knee surgery, i use tb4, bpc157 and ...
- claim_ids: c27
- hash: `006e6ba9e7eaac5d`

### s23 · youtube · http_429
- title: What Science ACTUALLY Says About BPC 157 Benefits
- url: https://www.youtube.com/watch?v=gaQwrB8HW4o
- summary: YouTube video reviewing scientific evidence on BPC-157, emphasizing lack of robust human RCTs.
- quote: However, its effectiveness and safety in humans remain unproven due to the lack of rigorous clinical trials. The only human study found was small and inconclusive, making it difficult to ascertain BPC 157's true benefits.
- claim_ids: c28
- hash: `c77d1852d31dc25f`

### s24 · pubmed · ok
- title: The Role of BPC-157 in Tissue Repair and Pain Management
- url: https://pubmed.ncbi.nlm.nih.gov/41898733/
- summary: 2026 review on BPC-157's reparative and anti-inflammatory properties in preclinical models, noting need for more human data.
- quote: BPC-157 remains a promising candidate for regenerative medicine, yet comprehensive evaluation is required before clinical translation can be recommended.
- claim_ids: c11
- hash: `dc569e11784f70fa`

### s25 · pubmed · ok
- title: Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review
- url: https://pubmed.ncbi.nlm.nih.gov/41754849/
- summary: 2026 systematic review comparing BPC-157 to growth factors for musculoskeletal injuries, highlighting its consistent efficacy in rat studies across administration routes.
- quote: Contrarily, proposed as a cytoprotection mediator, BPC 157 acts alone with a full cytoprotection range, given systemically or locally.
- claim_ids: c30
- hash: `fbe2d71f936818fd`

### s26 · pubmed · ok
- title: Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
- summary: 2025 review on BPC-157's pleiotropic effects and potential medical applications from literature and patents.
- quote: BPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects
- claim_ids: c31
- hash: `9f6d3181a92f76ba`

### s27 · news · ok
- title: BPC-157 – No Proof Required!
- url: https://www.mcgill.ca/oss/article/medical-critical-thinking-health-and-nutrition-contributors/body-protection-compound-no-proof-required
- summary: 2026 McGill OSS article critically examining limited human evidence for BPC-157 and ongoing clinical trial.
- quote: To date, only 3 publications have reported on the administration of BPC 157 to humans.
- claim_ids: c11
- hash: `400f254477a06e33`

### s28 · pubmed · ok
- title: From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC13026520/
- summary: 2026 review detailing BPC-157 mechanisms in tissue repair and pain management from preclinical studies.
- quote: Experimental evidence reveals that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways
- claim_ids: c11
- hash: `138f89affe3e9316`

### s29 · reddit · ok
- title: Bpc 157 - bad experience
- url: https://www.reddit.com/r/TBI/comments/1ol0pzt/bpc_157_bad_experience/
- summary: User with TBI history reports severe adverse effects from BPC-157 + TB500 including dizziness, migraine, stomach issues, and worsened symptoms shortly after low dose injection; partially recovered after a week but notes lingering effects.
- quote: I injected the low starting dose Wednesday and within 2 hrs afterwards I had extreme dizziness, a terrible migraine, upset stomach, and couldn’t handle any stimulation. 
 
 It is now Friday and I still feel horrible. My migraine has only subsided a little bit. I’m still neuro fatigued from it, more dizzy than my baseline along with more overall pain along with very irritable.
- claim_ids: c34
- hash: `db17af9eb59f77c2`

### s30 · reddit · ok
- title: Bpc 157. Anyone got any experience?
- url: https://www.reddit.com/r/Sprinting/comments/1d6q59g/bpc_157_anyone_got_any_experience/
- summary: User reports significant improvement in chronic knee pain (chondromalacia and meniscus issues) after 12 weeks of BPC-157 (250-750mcg daily) + TB500, allowing return to high-impact activities like squatting and flips with minimal next-day issues.
- quote: Yes I had fantastic results with bpc157 and tb500. I was feeling pretty hopeless with daily pain in both knees. ... Now I'm landing front flips on trampoline, kick flip on skateboard and front squatting 150lbs for reps and the following day is not a big issue now. Not saying it's cured but it's very much improved.
- claim_ids: c35
- hash: `ed29d43240af0fc3`

### s31 · reddit · ok
- title: My experience case study recovering from an A2 tear + A1 strain with BPC-157
- url: https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/
- summary: Climber reports subjective faster tendon healing and reduced lingering pain from A2 pulley tear using BPC-157 compared to prior injuries, though notes some new pains post-recovery.
- quote: I do believe BPC-157 helped me rebuild tendon integrity MUCH faster than my previous tendon injury experiences -but I am not experiencing some lingering pains which I did not have before. ... Within 1 week, it felt like the A2 had significant recovery ... I continued this routine with the subjective feeling that my injury was healing MUCH faster and building much more integrity than previous injuries which had taken 6+ months to heal.
- claim_ids: c36
- hash: `a3813e77670a95ff`

### s32 · pubmed · ok
- title: Pentadecapeptide BPC 157 and the central nervous system
- url: https://pubmed.ncbi.nlm.nih.gov/34380875/
- summary: 2022 review on BPC-157 effects on CNS, gut-brain axis, and potential in neurological disorders from animal studies.
- quote: We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157 , BPC 157 counteracted bilateral clamping of the common carotid ...
- claim_ids: c37
- hash: `134b5a5893551dab`

### s33 · news · ok
- title: BPC-157: Miracle Healing Peptide or Hidden Danger?
- url: https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger
- summary: 2025 article reviewing limited human data, safety concerns, and lack of rigorous trials for BPC-157.
- quote: In summary, human evidence on BPC-157 is scant and of low quality . The few available human studies are small, unblinded, and often conducted by clinics with a stake in the outcome.
- claim_ids: c38
- hash: `728917b068c60d53`

### s34 · reddit · ok
- title: BPC-157 weird side effects
- url: https://www.reddit.com/r/Biohackers/comments/1rj388r/bpc157_weird_side_effects/
- summary: User reports unusual side effects like persistent issues after stopping oral BPC-157 for shoulder/neck pain.
- quote: I began taking BPC-157 from Apeiron Elementals orally about 5 weeks ago to address a nagging neck/shoulder issue... I stopped taking the BPC-157 about 1.5 weeks ago, but I'm still having this issue.
- claim_ids: c39
- hash: `6bcaca9fda8675d3`

### s35 · reddit · ok
- title: BPC 157 - to try or not try
- url: https://www.reddit.com/r/PsoriaticArthritis/comments/1slrzul/bpc_157_to_try_or_not_try/
- summary: Discussion on using BPC-157 for psoriatic arthritis enthesitis, mixed user experiences with inflammation and recovery.
- quote: My rheumatologist is suggesting I try BPC157 for enthesitis relief, because I am already on a biologic for a different autoimmune disease.
- claim_ids: c40
- hash: `1d69a96877e350c7`

### s36 · news · ok
- title: BPC-157 and the Difference Between an Evidence Gap and a Cover-Up
- url: https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up
- summary: 2026 analysis of BPC-157 evidence base, human data limitations, and regulatory investigations.
- quote: In rodent models, BPC-157 accelerates tendon healing, gastric ulcer closure, skin and muscle wound repair , and recovery from several forms of ...
- claim_ids: c41
- hash: `7f0864268f11d970`

### s37 · pubmed · ok
- title: Stable Gastric Pentadecapeptide BPC 157 and Striated, ...
- url: https://pubmed.ncbi.nlm.nih.gov/36551977/
- summary: 2022 review on BPC-157 for muscle-tendon junction healing in animal models.
- quote: We review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy.
- claim_ids: c42
- hash: `784d345650c0e056`

### s38 · pubmed · ok
- title: BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide
- url: https://pubmed.ncbi.nlm.nih.gov/41155565/
- summary: 2025 review on BPC-157's effects on angiogenesis, NO system, and potential medical applications.
- quote: BPC 157 exhibits a distinctive effect on NO-level (increase vs. decrease), always combined with counteraction of free radicals formation, and in ...
- claim_ids: c43
- hash: `85ce797eda9e879c`

### s39 · pubmed · ok
- title: S808 Oral Peptide BPC-157—An Emerging Adjunct to Gastrointestinal Therapies?
- url: https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx
- summary: 2025 systematic review on oral BPC-157 for GI therapies.
- quote: BPC-157 shows promise from pre- clinical studies for a range of GI pathologies—particularly in mucosal protection, wound healing, inflammatory bowel disease, and ...
- claim_ids: c44
- hash: `8704017d6a569d7b`

### s40 · news · ok
- title: Peptides in Orthopedics: BPC-157 — What Patients Should Know About Safety, Efficacy, and Sourcing
- url: https://www.mdorthospecialists.com/2026/04/28/peptides-in-orthopedics-bpc-157-what-patients-should-know-about-safety-efficacy-and-sourcing/
- summary: 2026 orthopedic clinic article discussing preclinical evidence and limited human data for BPC-157.
- quote: virtually all of the robust evidence for BPC-157 comes from animal studies, not human clinical trials.
- claim_ids: c11
- hash: `ce830ec70bfaedb7`

### s41 · reddit · ok
- title: BPC-157 peptide? : r/eds
- url: https://www.reddit.com/r/eds/comments/1afrxql/bpc157_peptide/
- summary: Anecdotal experiences with BPC-157 for EDS and joint issues from 2024-2026 thread.
- quote: I used BPC-157 and it seemed to help clear lingering injuries, and I was able to bounce back from minor twinges and stuff during exercise that would have lingered otherwise.
- claim_ids: c46
- hash: `43b980df3ebe65de`

## Provenance (181 model passes)
- chain valid: yes · head: `10774e844a8162e6`

- ask · grok/grok-4.3 · 2026-07-11T14:38 · hash `48d433c74ab8`
- sources · ingest:deterministic · 2026-07-11T14:38 · hash `53e63f21c0e3`
- ask · grok/grok-4.3 · 2026-07-11T14:38 · hash `46d40e539456`
- ask · grok/grok-4.3 · 2026-07-11T14:39 · hash `68acdaa4e0f1`
- sources · ingest:deterministic · 2026-07-11T14:39 · hash `88b67b054fe9`
- voxel_divide · owner · 2026-07-17T02:38 · hash `de787dea24c6`
- claim · user · 2026-07-22T20:12 · hash `0716e3b20a97`
- claim · user · 2026-07-22T20:12 · hash `10774e844a81`

## Question graph
- questions: 8 · evidence ingests: 8
- **qn_bpc_157_selftest_graph_fn_what_good_and_bad_expe_afa83466** [gap] SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?
  - gaps: No large-scale human trials; optimal dose/route/duration unknown; interactions unknown; long-term safety unknown
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_241eb02b** [enriched] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No imaging-confirmed outcomes; no long-term follow-up; no interaction data specific to herniated-disc patients or common spine medications.
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac** [enriched] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: No controlled human trials for herniated-disc outcomes; No data on BPC-157/TB-500 interactions or safety in disc pathology; No coverage of other peptides (e.g., ARA-290) for herniated discs in the provided slugs
- **qn_bpc_157_what_good_and_bad_experiences_are_logged_a598a82c** [gap] what good and bad experiences are logged for BPC-157?
  - gaps: long-term human safety data; optimal human dosing/route/duration; controlled human efficacy trials; drug/condition interaction data
- **qn_bpc_157_selftest_graph_fn_what_good_and_bad_expe_fd4bdde2** [gap] SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?
  - gaps: long-term human safety data absent; no dosing or protocol information; unknown interactions with medications or conditions; no controlled human efficacy trials
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7** [enriched] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No controlled human data for herniated discs; anecdotes are n=1, self-reported, no imaging follow-up.
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319** [enriched] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: no human controlled data for disc herniation; no interaction data; no ARA-290 or TB-500 herniated-disc coverage in topology; long-term safety absent
- **qn_bpc_157_selftest_graph_fn_what_good_and_bad_expe_5ca2a402** [gap] SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?
  - gaps: Long-term human safety data absent (c67); no dosing, protocol, or treatment recommendations exist in catalogue (c120); only three small human reports noted in reviews (c24); unknown interactions with medications or conditions.

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/bpc-157/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/bpc-157/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"bpc-157","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest bpc-157|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim bpc-157|tier|assertion`
- **iMessage ask:** `bpc-157|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `bpc-157`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/bpc-157/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/bpc-157/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*